|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.24 USD | +0.99% |
|
+0.40% | +82.76% |
| 07-10 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 05-15 | ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 102M | - | - | - | - | - |
| 1,089B | |||||
| 643B | |||||
| 465B | |||||
| 359B | |||||
| 303B |
- Stock Market
- Stocks
- ICCC Stock
- Charts ImmuCell Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
